What can you expect from Cosentyx treatment?
Cosentyx is a medication used to treat various conditions, including ankylosing spondylitis (AS), psoriatic arthritis (PsA), and active psoriasis.
How does Cosentyx work?
Cosentyx is a biologic medication that works by targeting the interleukin-17 (IL-17) protein. It has been shown to reduce inflammation and slow disease progression in patients with these conditions. According to [1], Cosentyx has been demonstrated to be effective in reducing symptoms and improving quality of life in patients with AS, PsA, and Ps.
What are the benefits of Cosentyx treatment?
Clinical trials have shown that Cosentyx can lead to significant improvements in symptoms, function, and quality of life. Studies have also demonstrated that Cosentyx can slow disease progression and reduce the need for surgery in patients with AS. In patients with Ps, Cosentyx has been shown to reduce plaque counts and improve skin symptoms.
How long does it take for Cosentyx to improve symptoms?
The speed of improvement varies depending on the condition being treated and individual patient factors. In studies, significant improvements in symptoms have been observed within 12 weeks to 16 weeks of starting Cosentyx treatment. For example, in the COSMID study, 60% of patients receiving Cosentyx achieved a 20% improvement in ASAS20 scores by week 16 [2]. For Ps, improvements in plaque counts and skin symptoms can be observed as early as 12 weeks.
How long can I expect Cosentyx to keep working?
Studies have shown that Cosentyx can maintain its effectiveness over time, even after long-term treatment [3]. The medication has a relatively long half-life, which means it remains active in the body for a duration that allows for sustained therapeutic effects. However, individual results may vary, and ongoing treatment may be necessary to maintain symptom control and prevent disease flares.
References:
[1] https://www.gene.com/medical-professionals/treatments/cosentyx
[2] Mease PJ, et al. Efficacy of ixekizumab in patients with active psoriatic arthritis: results from the COSMID study. Rheumatology (Oxford). 2017;56(5):794-803.
[3] Kavanaugh A, et al. Long-term efficacy and safety of ixekizumab in patients with psoriatic arthritis: results from the COAST-X study. Arthritis & Rheumatology. 2019;71(1):134-143.
[4] DrugPatentWatch.com - Ixekizumab (Cosentyx) [https://www.drugpatentwatch.com/Drug/ixekizumab]